TY - JOUR
T1 - Acute heart failure and iron deficiency: a prospective, multicentre, observational study
AU - van Dalen, D.H.
AU - Kragten, J.A.
AU - Emans, M.E.
AU - Van Ofwegen-Hanekamp, C.E.E.
AU - Klaarwater, C.C.R.
AU - Spanjers, M.H.A.
AU - Hendrick, R.
AU - van Deursen, C.T.B.M.
AU - Brunner-La Rocca, H.P.
N1 - Funding Information:
This work was supported by Vifor Pharma, Ltd., Glattbrugg, Switzerland, and the Dutch Network for Cardiovascular Research (WCN). However, as this was an investigator‐initiated study, Vifor Pharma had no role in the design of the trial, the enrolment of the patients, the collection, analysis or interpretation of the data, and the writing and publication of the manuscript.
Publisher Copyright:
© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
PY - 2022/2
Y1 - 2022/2
N2 - Aims The prevalence and the natural course of iron deficiency (ID) in acute heart failure (AHF) are still unclear. We investigated the prevalence of ID in unselected patients admitted with AHF on admission, at discharge and up to 3 months thereafter.Methods and results In this prospective, multicentre, observational study, 742 patients admitted with AHF were enrolled. The main study outcome was the percentage of patients with ID (ferritin or ferritin 100-299 mu g/L and transferrin saturation <20% = functional ID) at admission (T0), after clinical stabilization prior to discharge (T1), and 10 +/- 6 weeks after discharge (T2). At T0, ID was present in 71.8% of the patients (44.1% absolute and 27.7% functional ID). At T1 and T2, ID was present in 56.4% (32.4% absolute and 24% functional ID) and 50.3% (36.8% absolute and 13.5% functional ID), respectively. Absolute ID persisted from T0 to T2 in 66% of the patients, while functional ID resolved in 56% of the patients. Ferritin (median [interquartile range] 124 mu g/L [56-247] to 150 mu g/L [73-277]), transferrin saturation (15% [10-20] to 18% [12-27]), and iron levels (9 mu mol/L [6-13] to 11 mu mol/L [8-16]) increased significantly (all P < 0.001) from T0 to T1. Transferrin saturation (to 21% [15-29]) and iron levels (to 13 mu mol/L [9-17]) also increased significantly (both P < 0.01) from T1 to T2 without iron supplementation.Conclusions Iron deficiency is highly prevalent in patients with AHF, but resolves during treatment in some patients, even without iron supplementation. Absolute ID is more likely to persist over time, whereas functional ID often resolves during treatment of AHF, representing probably a reduced iron availability rather than a true deficiency.
AB - Aims The prevalence and the natural course of iron deficiency (ID) in acute heart failure (AHF) are still unclear. We investigated the prevalence of ID in unselected patients admitted with AHF on admission, at discharge and up to 3 months thereafter.Methods and results In this prospective, multicentre, observational study, 742 patients admitted with AHF were enrolled. The main study outcome was the percentage of patients with ID (ferritin or ferritin 100-299 mu g/L and transferrin saturation <20% = functional ID) at admission (T0), after clinical stabilization prior to discharge (T1), and 10 +/- 6 weeks after discharge (T2). At T0, ID was present in 71.8% of the patients (44.1% absolute and 27.7% functional ID). At T1 and T2, ID was present in 56.4% (32.4% absolute and 24% functional ID) and 50.3% (36.8% absolute and 13.5% functional ID), respectively. Absolute ID persisted from T0 to T2 in 66% of the patients, while functional ID resolved in 56% of the patients. Ferritin (median [interquartile range] 124 mu g/L [56-247] to 150 mu g/L [73-277]), transferrin saturation (15% [10-20] to 18% [12-27]), and iron levels (9 mu mol/L [6-13] to 11 mu mol/L [8-16]) increased significantly (all P < 0.001) from T0 to T1. Transferrin saturation (to 21% [15-29]) and iron levels (to 13 mu mol/L [9-17]) also increased significantly (both P < 0.01) from T1 to T2 without iron supplementation.Conclusions Iron deficiency is highly prevalent in patients with AHF, but resolves during treatment in some patients, even without iron supplementation. Absolute ID is more likely to persist over time, whereas functional ID often resolves during treatment of AHF, representing probably a reduced iron availability rather than a true deficiency.
KW - Acute decompensated heart failure
KW - Iron deficiency
KW - Worsening heart failure
KW - Comorbidity
KW - Functional iron deficiency
KW - Iron availability disorder
KW - ANEMIA
KW - PREVALENCE
KW - DIAGNOSIS
U2 - 10.1002/ehf2.13737
DO - 10.1002/ehf2.13737
M3 - Article
C2 - 34862747
SN - 2055-5822
VL - 9
SP - 398
EP - 407
JO - Esc heart failure
JF - Esc heart failure
IS - 1
ER -